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Abstract
The quarter century since the foundation of the
Royal College of Ophthalmologists has coin-
cided with immense change in the subspecialty
of medical retina, which has moved from being
the province of a few dedicated enthusiasts to
being an integral, core part of ophthalmology
in every eye department. In age-related macular
degeneration, there has been a move away from
targeted, destructive laser therapy, dependent
on fluorescein angiography to intravitreal
injection therapy of anti-growth factor agents,
largely guided by optical coherence tomography.
As a result of these changes, ophthal-
mologists have witnessed a marked improve-
ment in visual outcomes for their patients with
wet age-related macular degeneration (AMD),
while at the same time developing and enact-
ing entirely novel ways of delivering care. In
the field of diabetic retinopathy, this period
also saw advances in laser technology and a
move away from highly destructive laser
photocoagulation treatment to gentler retinal
laser treatments. The introduction of intravi-
treal therapies, both steroids and anti-growth
factor agents, has further advanced the treat-
ment of diabetic macular oedema. This era has
also seen in the United Kingdom the intro-
duction of a coordinated national diabetic
retinopathy screening programme, which
offers an increasing hope that the burden of
blindness from diabetic eye disease can be
lessened. Exciting future advances in retinal
imaging, genetics, and pharmacology will
allow us to further improve outcomes for our
patients and for ophthalmologists specialising
in medical retina, the future looks very
exciting but increasingly busy.
Eye (2014) 0, 000–000. doi:10.1038/eye.2014.141
Introduction
It could reasonably be argued that in the field of
ophthalmology, the subspecialty of medical
retina has undergone the most extensive
developments in practice over the past quarter
of a century. It is a period that has seen major
progress in ophthalmic imaging of the ocular
fundus, and huge progress in the management
of the major retinal conditions, namely age-
related macular degeneration (AMD), diabetic
retinopathy, and retino-vascular disorders. This
period has encompasses a move away from the
destructive, targeted laser treatments of retinal
lesions with inevitable unwanted collateral
retinal damage, to pharmacological
interventions with improved visual outcomes.
I was appointed as a NHS consultant
ophthalmologist in Birmingham in 1986, and
therefore I have experienced at first hand many
of the changes that have occurred in medical
retina within the last 25 years.
In 1988, the ophthalmic world in the United
Kingdom was very different from now, and
Birmingham was probably fairly typical of
large city services, with a ‘hub and spoke’
configuration of its services. In 1988, there were
only 10 ophthalmic consultants providing
services to the greater Birmingham Area, 9 of
whom had sessions at the ‘hub’, the
Birmingham and Midland Eye Hospital, which
provided regional and subregional eye
services, and subspecialty services. The same
consultants also provided general
ophthalmology services at the district general
‘spoke’ hospitals within Birmingham. In
contrast in 2013, there are over 50 consultants
providing ophthalmic services to the same
geographic area, with well-developed
ophthalmic units in all the major hospitals
within the Birmingham conurbation.
In 1988, subspecialist training in the United
Kingdom was in its infancy, and apart from
those consultants working in larger centres, the
vast majority of consultants were generalists,
providing care for a wide range of ophthalmic
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disorders. At this time, medical retina was an embryonic
subspecialty and for many patients laser
photocoagulation and fundus fluorescein angiography
(FFA) services were not provided at the local district
general hospital, necessitating referral and travel to a
larger centre with inevitable delays.
In the context of these major changes in the provision
of ophthalmic services in the United Kingdom, I will now
consider the major advances that have occurred in the
management of medical retina disorders.
Age-related macular degeneration
For patients with wet AMD in 1988, the outlook was
fairly bleak. It had been known for some years that
choroidal neovascular (CNV) membranes were
aggressive and grew quickly under the fovea, and that
there was a high risk of fellow-eye involvement.1 The
Macular Photocoagulation Study had shown that 73% of
untreated extrafoveal CNV became subfoveal within 1
year2 and it had also been shown that CNV edge growth
rates were 5–10mm per day.3 It had also been shown in
randomised clinical trials by the Macular Photocoagulation
Study Group4 and by the Moorfields Macular Study
Group5 that laser photocoagulation with argon blue-
green laser could reduce vision loss by460% in patients
with CNV 4200 mm from the centre of the foveal
avascular zone.
Laser photocoagulation for wet AMD
The technique of laser treatment of CNV required high
energy laser with 0.1 to 0.2-s duration, to create an
intense white laser burn that covered and overlapped the
CNV as visualised on the FFA. For well defined,
extrafoveal lesions, the treatment was relatively
straightforward, but even in these cases failure did occur
when there was recurrence and regrowth of the lesion,
which occurred in close to half of cases followed up for 3
years.6 An important part of the treatment was to overlap
the CNV edge by at least 100mm, which in juxtafoveal
cases on the foveal side was not for the faint-hearted
ophthalmologist!
In most cases this treatment required a retro-bulbar
local anaesthesia injection, to minimise pain for the
patient but more importantly to reduce inadvertent
ocular movement during laser, and it required immediate
post-laser FFA to check that the entire CNV was covered.
It can be seen that this treatment was probably best left to
specialist macular services of which there were at this
time very few.
The choice of laser wavelength was probably not as
important as the proper placement and correct intensity
of the burns, but it soon became apparent that argon
blue-green was best avoided for juxtafoveal CNV due to
inner retinal damage caused by xanthophyll pigment
absorption. Argon green therefore became the
commonest option although at the Birmingham and
Midland Eye Hospital we also used multiple wavelength
lasers and later on the infrared diode laser, all of which
had been shown to be effective.7,8
Generally patients with retinal pigment epithelial
detachments (PEDs) were not treated with laser after the
Moorfields Macular Study Group had failed to show any
benefit of treatment for avascular PED, although the
situation for vascularised PED was less clear.9 Retinal
pigment epithelial tears, which had been first described
at Moorfields Eye Hospital in 1981,10 became a
recognisable complication of this type of laser.
A longer-term problem with laser treatment for CNV is
the longer-term enlargement and creepage of the scar
toward the fovea over time. This is demonstrated in
Figure 1, which shows the effect of successful
photocoagulation in a young patient with idiopathic
CNV and subsequent enlargement of the scar over a
10-year period.
Treatment of subfoveal CNV
The difficult scenario of treating patients with wet AMD
where some part of the lesion was under the fovea
remained a problem. The Macular Photocoagulation
Study Group carried out a subfoveal laser therapy trial,
which treated patients at an early stage. The results
showed that over a 2-year period the treated group did
marginally better than the untreated, in terms of lines of
visual acuity and contrast sensitivity, but the trade off
was a large decrease in the vision immediately after
treatment. As a result, this treatment did not prove
popular with patients or ophthalmologists.11
Scatter laser therapy to the lesion in subfoveal CNV
was not found to be beneficial,12 and systemic interferon
therapy, which had shown benefit in a very small initial
case series,13 was shown to be ineffective when tested in
proper clinical trials.14,15 Ionising radiation, which can
inactivate rapidly proliferating cells, such as occurs in
CNV, was used in several trials in subfoveal CNV.
Overall, the results of these trials were disappointing and
it was not used in widespread clinical practice at that
time,16,17 although subsequently it is now being re-
evaluated in the light of new developments.
The introduction of indocyanine green (ICG) video
angiography lead to much interest in the possibility of
identifying and treating feeder vessels to CNV, thus
avoiding potentially damaging collateral laser damage to
the fovea. It also lead to renewed interest in the
possibility of treating poorly defined, occult CNV
with laser photocoagulation, which had recognisable
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hot spots on ICG.18,19 Ultimately, however, ICG probably
did not fully live up to its initial promise as an adjunct
for laser photocoagulation, although it did allow some
cases to be treated with ICG dye enhanced laser, as a
form of early photodynamic therapy (PDT).20 ICG did,
however, transform our understanding of the choroid
and CNV and as we shall see, has today become a key
investigation for several retinal and choroidal conditions.
Photodynamic laser therapy with verteporfin
PDT was a major breakthrough because it allowed for the
first time subfoveal CNV to be successfully treated, and
was shown in large-scale randomised clinical trials to
reduce the risk of vision loss in selected cases of AMD
with CNV.21 PDT is a two-stage procedure performed as
an outpatient basis: the first step is a 10-min intravenous
infusion of a light-sensitising drug, verteporfin, a
benzoporphyrin derivative, which is lipophilic and taken
up by plasma membrane cells, within the CNV. The
second stage is the activation of the verteporfin dye by
irradiation of the CNV with a non-thermal diode laser of
wavelength 689 nm, which delivers a dose of 50 J/cm2
over a period of 83 s.22
The treatment of AMD with PDT (TAP) Trial, was a
large randomised controlled trial that investigated the
effectiveness of PDT compared with placebo in patients
with subfoveal CNV. The key eligibility criteria was best-
corrected visual acuity of 20/40–20/200, subfoveal CNV
secondary to AMD with evidence of classic CNV and a
greatest linear dimension of the entire lesion of 5400 mm
or less. Categorisation of the CNV lesion on FFA was of
major importance, the identification of the proportion of
the lesion that was ‘classic’ and ‘occult’ relied on
meticulous analysis of the FFA images. The treatment
spot size was determined by measuring the entire lesion
on FFA and adding 1000 mm, to achieve a 500mm margin
of overlap at the margin of the lesion to ensure that the
entire lesion was covered.
Patient selection criteria include the following: (1) in
cases due to AMD, lesion composition of (a)
predominantly classic CNV, (b) occult with no classic
CNV with presumed recent disease progression, or (c)
relatively small minimally classic lesions.
Figure 1 Small extrafoveal CNV treated with argon green laser photocoagulation in 1989. (a) FFA pre-laser. (b) Red-free photograph
immediately post-laser showing overlapping, confluent burns. (c) Fluorescein angiography 1-week post-laser treatment. (d) Late phase
fluorescein angiography in 1999 showing laser creep and scar extension toward fovea.
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In the TAP Study, the benefits of PDT were most clearly
seen in ‘predominant classic’ lesions with no occult
component, where 23% of verteporfin-treated eyes had at
least moderate vision loss at 12 months, compared with
73% of placebo-treated eyes.21 This study and others
showed that PDT with verteporfin in AMD cases with
subfoveal CNV showed that therapy was safe23 and
reduced the risk of moderate and severe vision loss in
patients with subfoveal lesions that are predominantly
classic CNV secondary to AMD.24 In time, this and other
studies enabled guidelines regarding PDT in AMD for
medical retina specialists to be created.25,26
Photodynamic combination therapy and use in other
conditions
PDT with verteporfin was shown to be effective in
younger patients with idiopathic CNV27 and the VIP
Study showed that PDT was better than placebo in cases
of CNV secondary to pathological myopia.28 However,
studies with ICG angiography had shown in some AMD
cases that collateral damage of the healthy choroidal
vasculature had occurred, with repeated PDT treatments
and this raised concerns about the side effects of
reducing normal choroidal perfusion, and the influence
of this on the visual outcome of the treatment.29 These
observations lead to an acceptance that PDT was not
entirely without risk and that where possible reduced
light doses should be used.30
PDT combined with intravitreal triamcininolone for
AMD was shown to be effective and initial reports were
encouraging, with better visual outcomes and less laser
treatments being required.31,32 Attention also turned to
combining full or reduced fluence verteporfin, with
ranibizumab or bevacizumab, powerful anti-
antiangiogenic agents. Although combination therapy
appears to be safe and effective, comparative studies
have not shown any improvement or reduction in vision
when compared with anti-angiogenic monotherapy with
ranibizumab or bevacizumab alone.33–35 The vaso-
occlusive effects of PDT may excite some deleterious
inflammatory effects in the surrounding tissues and
therefore some ophthalmologists have recommended
so-called triple therapy—namely intravitreal anti-
vascular growth factor (VEGF) agent, PDT with
verteporfin and intravitreal steroid. This technique has
been shown to be effective in certain cases of CNV but is
not currently in widespread use.36
PDT has also been used and shown to be effective in
the treatment of choroidal haemangioma,37 chronic
central serous retinopathy,38 and in polypoidal
vasculopathy, where it has been shown to be superior to
ranibizumab.39
Anti-angiogenic agents in AMD
Anti-angiogenic therapy has transformed the treatment in
wet AMD, with improved visual outcomes over PDT
monotherapy, and ranibizumab and bevacizumab are
currently the gold-standard care. ANCHOR and MARINA,
large, multicentre, randomised clinical trials showed that a
fixed monthly dosing regime of ranibizumab gave
extremely good visual outcomes in all subtypes of wet
AMD.40,41 However, monthly injections place a huge
burden on both patients and health providers and this lead
to other treatment regimes being investigated.
The PIER study showed that close monitoring and
retreatment are still necessary to maintain the optimal
visual results.42 The PrONTO Study, using an OCT-guided
variable-dosing regimen with intravitreal ranibizumab
resulted in VA outcomes comparable to the outcomes
from the phase III clinical studies, but fewer intravitreal
injections were required.43,44 Despite being a small study
of 40 patients, the protocol of this study has formed the
basis for guidance TA 155 issued by the National Institute
for Health and Care Excellence (NICE) in 2008 for the
treatment of wet AMD in the NHS.45 In this guidance,
pegaptanib a selective anti-VEGF agent was compared
with ranibizumab and found not to be cost effective.
The clear benefits of intravitreal anti-VEGF drugs over
PDT laser therapy led to a rapid transition from PDT to
the introduction of ranibizumab in the United Kingdom.
This can be seen in my personal experience at the
Birmingham and Midland Eye Centre where the number
of PDT laser treatments declined from 160 per month or
more to less than 5 per month in the period 2007–2010,
and it has now declined even further. PDT is mainly now
only being used for polypoidal vasculopathy and chronic
central serous chorioretinopathy.
The provision of AMD services in the NHS accordingly
underwent a reformation at this time, and it was
recognised that the ‘PDT model’ was no longer going to
be viable. For PDT services in the United Kingdom,
treatment and assessment had been limited to 40 or so
larger ophthalmic units who had access to medical retina
expertise. For anti-VEGF services, it was realised that
greater numbers of patients would be eligible for
treatment, with more frequent monitoring and treatment
visits, and a new service delivery model was required.
This led to considerable debate within the Royal College
of Ophthalmologists about the configuration of the new
services and in July 2007, the publication of guidelines
for ophthalmologists and health-care commissioners.46
Diabetic retinopathy
The quarter century from 1988 to 2013 witnessed important
progress in the management of diabetic retinopathy, with
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developments in laser technology, ophthalmic imaging,
and drugs targeted to the retina. However, possibly the
greatest impact in the United Kingdom was the
introduction of a national diabetic retinopathy screening
programme in the four devolved nations.
The provision of diabetic eye services in the United
Kingdom in 1988 was patchy, and access to laser
photocoagulation services and expertise was often
difficult for patients outside the larger centres. As early
as 1978, Professor Eva Kohner had outlined a blue-print
of optimal care, which had emphasised the need for close
collaboration between ophthalmologists and diabetic
physicians, the provision of regional centres for
assessment and treatment of diabetic retinopathy, and
the importance of screening and diabetic control.47
Professor Kohner had commented in this paper that ‘if
physicians and ophthalmologists work together,
blindness may indeed be prevented in diabetic patients’
and at East Birmingham Hospital, (subsequently
Birmingham Heartlands) where I was based, we took this
advice to heart by setting up a combined diabetic eye
clinic, which was led by myself an ophthalmologist and
Professor Paul Dodson, a diabetic physician. Although
for us this worked exceptionally well in improving
patient care, facilitating teaching, training, and research,
it was not unfortunately a model that was copied
elsewhere to my knowledge, but it was certainly
beneficial in improving our clinical service.48–52
Laser photocoagulation
The success of laser photocoagulation in preventing
blindness in diabetic retinopathy had been demonstrated
in a number of earlier, landmark clinic trials. The Diabetic
Retinopathy Study (DRS) had clearly shown that timely
pan-retinal argon laser photocoagulation could reduce the
risk of severe visual loss by at least half and had far less
harmful side effects than xenon light coagulation.53 In
addition, it had also introduced the concept of ‘high-risk’
characteristics for proliferative diabetic retinopathy (PDR),
which enabled ophthalmologists to identify and treat
patients appropriately.54 The Early Treatment Diabetic
Retinopathy Study (ETDRS) further refined our
knowledge of when to treat patients with PDR, and
showed that scatter argon laser photocoagulation was
not beneficial in mild and moderate non-proliferative
(pre-proliferative phase), if careful monitoring in these
cases can be maintained.55
Until the 1980s, the importance of macular oedema as a
cause of visual loss in diabetic patients was
underestimated by most ophthalmologists and diabetic
physicians. However, the reports from the Wisconsin
Epidemiological Study provided the best data on the
epidemiology of diabetic macular oedema, and raised the
awareness of this condition.56–58 The ETDRS further
defined and classified diabetic macular oedema, and
produced important information about the treatment of
this condition59,60 and appropriate photocoagulation and
laser settings.61 The concept of ‘clinically significant
macular oedema’ was introduced by the ETDRS because
it was shown that laser treatment was beneficial if this
was present, and could reduce the risk of significant
visual loss by about 50%.
Following these landmark studies, it was recognised that
laser photocoagulation services should be provided in
most ophthalmology departments, which would enable
patients to receive early and timely laser photocoagulation
locally. Most ophthalmologists at this time also switched
away from using argon blue-green laser because of the
perceived risk to the operator and increased collateral
damage to the patient when treating near the macula. In
fact for a short period, a monitoring system was introduced
as part of a research project, to screen the colour vision of
ophthalmologists performing laser, to detect laser-induced
colour vision damage, on a volunteer basis.62
With improvements in laser technology, and the
introduction of solid state laser machines, it has been
recognised that heavy laser burns in diabetic retinopathy
are unnecessary for effective treatment and collateral
damage to the retina can be minimised, by reducing laser
exposure times63,64 (Figure 2).
This in turn has led to effective strategies to reduce
patient’s discomfort during pan-retinal laser
photocoagulation by deliberately choosing shorter
exposure times, while still providing effective
treatment.65 More recent advances have continued to
improve the experience of patients undergoing retinal
laser photocoagulation by using pattern scanning laser
machines, which allow ophthalmologists to perform the
treatment much quicker and with less discomfort.66
Intravitreal therapy for diabetic maculopathy
Although laser photocoagulation had been the mainstay
of treatment for diabetic maculopathy since the early
1980s, it was recognised that not all patients responded
well to treatment. In particular, patients with diffuse
macular thickening and with ischaemic changes did
poorly with laser treatment. Other treatment options
were therefore investigated and the IDRCR.Net
performed a randomised controlled trial comparing
modified EDTRS laser photocoagulation with either 1 or
4 mg of preservative free intravitreal triamcinolone.
Despite an initial improvement in vision and retinal
thickness in the 4 mg triamcinolone group, overall the
laser group did better at 1 and 2 years, even when the
effect of cataract formation with triamcinolone was
considered.67
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However, increasing evidence from trials of
intravitreal VEGF inhibitors is accumulating, which
suggests that the outcome in patients with diffuse
macular oedema is much improved. The BOLT
Study, which compared bevacizumab with laser68
and the landmark DRCR.Net study, which compared
ranibizumab, laser, and triamcinolone, have
shown that anti-VEGF therapy has become the new
gold standard treatment for diabetic macular
oedema.69
Screening for diabetic retinopathy
In 1988, diabetic retinopathy screening for diabetic
retinopathy was mostly opportunistic, performed by a
few dedicated enthusiasts, but with no co-ordinated
central organisation or guidelines, and with pupil
dilatation being optional. In addition, there was
considerable debate as to how screening should be
delivered, whether by fundus photography or direct
ophthalmoscopy, with and without mydriasis, and who
should be trained to perform it.70–75 Many of these
aspects were discussed at the Cambridge Ophthalmic
Symposium in 1992, which was chaired by Dr Angus
MacCuish a diabetic physician from Glasgow, who
emphasised the needs for pupillary dilatation, for
recruitment and training of personnel, and the
importance of having quality control.76
The development of DR screening in Europe had been
accelerated by the St Vincent Declaration, in 1989, which
set a target for reduction of new blindness by one-third,
in the following 5 years.77 In addition, several authors
had shown that DR screening was cost effective as a
means of preventing blindness from DR.78
In 1999, a national workshop was convened in
Glasgow by the National Screening Committee
(NSC) of the Department of Health and the Royal
College of Ophthalmologists (RCOphth), to consider
the introduction of national screening programmes in
the four devolved nations of the United Kingdom.
Subgroups were set up to consider technology,
training and education, grading, and quality
assurance. The key mantra of co-chairs of this
landmark meeting, Dr Muir Gray of the NSC and
Dr Jeffrey Jay, President of the RCOphth, was ‘simplify,
simplify, simplify!’
The introduction of digital cameras for fundus
photography enabled quality control to be obtained, and
was rapidly adopted as the gold standard by the national
screening programme.79 The final parts of the
photographic jigsaw was the validation that two field
fundus photography was just as good, and much easier
for photographer and patient, than seven standard field
fundus photography, which was the then gold standard
for clinical trials but impractical for large scale
screening.80,81
For grading, a subgroup of ophthalmologists, diabetic
physicians, and photographers was convened to develop
a simplified grading protocol82 for England and Wales,
which was based on the following principles:
K To detect any retinopathy
K To detect the presence of sight threatening retino-
pathy (STDR)
K To allow precise quality assurance at all steps
K To minimise false-positive referrals to the hospital eye
service.
Figure 2 Fundus photograph and OCT image of diabetic patient with threshold laser photocoagulation burns, showing how OCT can
facilitate subthreshold and threshold laser treatment.
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This led to the novel ‘R and M grades’, which were
introduced as a simple but accurate grading system,
which could be easily validated. In 2011–2012, in England
over 1.9 million persons with diabetes underwent
retinopathy screening, representing a coverage of 73.9%
of the population identified to have diabetes83 (Figure 3).
Retinal vascular disease
For the management of retinal vein occlusions for much
of the last 25 years, the best evidence has come from two
important clinical trials: the Branch Vein Occlusion Study
(BVOS) and the Central Vein Occlusion Study (CVOS).
The BVOS conclusively demonstrated the effectiveness of
argon laser photocoagulation for macular oedema84 and
retinal neovascularisation.85 However, the CVOS showed
that macular grid photocoagulation had no effect on the
visual prognosis in patients with macular oedema,86 but
in ischaemic cases, iris neovascularisation quickly
resolved after pan-retinal photocoagulation.87 In general
terms, therefore, there was not much ophthalmologists
had to offer patients who developed macular oedema
following central retinal vein occlusions.
However, the advent of intravitreal drug therapy has
markedly changed the options available in the last few
years. Intravitreal triamcinolone is effective in reducing
macular oedema but high rates of cataract formation and
raised intra-ocular pressure were of concern in the
SCORE Study.88 However, more recently a slow release,
dexamethasone intravitreal implant has been shown to
be effective with a better safety profile.89 Intravitreal
ranibizumab and bevacizumab have also been shown to
be highly effective in treating macular oedema in CVO.90
Imaging advances in medical retina service
The past 25 years have seen major advances in retinal
imaging. In the 1980s, we were almost entirely reliant on
film-based fluorescein angiography, for guiding laser
treatment, which in the case of wet AMD had to be
performed on an urgent basis. This required an in-house
medical photographer who would carry out the fundus
photography, undertake immediate film development,
and printing, and return it to the ophthalmologist with
patient to perform laser—all within the time confines of a
clinic (Figures 4 and 5).
This laborious process could be accelerated by using
Polaroid film,91 or by using video analysis, but did not
really improve until the advent of digital fundus
photography. Later on the use of ICG angiography
transformed our understanding of choroidal disorders92
and continues to be an important investigation in certain
Figure 3 Map of constituent parts of the Birmingham and Black Country Diabetic Retinopathy Screening Service. By 2010, when this
schematic map was created, there were 125 000 annual screens being performed, at 106 screening sites, referring into 7 hospital
ophthalmology departments.
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conditions,93,94 although probably less influential in
medical retina disease that was first expected.
By far the major imaging advance in the field of
medical retina has been optical coherence tomography
(OCT), which rapidly went from being a research
investigation, first reported in the early 1990s,95 to being
an essential part of the medical retina clinic in 2013.
Today OCT is an integral part of the assessment of all
macular diseases, and has become a key part of treatment
protocols for AMD, diabetic retinopathy, and retino-
vascular disorders. To meet the increasing workload of
busy clinics, ophthalmologists are increasingly turning to
their non-medical staff clinics to support in the provision
of services, such as by ‘virtual clinics’, whereby large
numbers of patients results can be quickly reviewed.96
Conclusion
Over the past 25 years enormous advances have taken
place in the way we manage the major medical retina
conditions. There has been a move away from targeted,
destructive, laser therapy to intravitreal pharmacological
interventions, blocking VEGF, and other growth factors.
The forthcoming challenge will be how ophthalmologists
deal with the ever increasing workload in medical retina
disease, while being able to incorporate the exciting
concepts of individualised health care that are promised
by recent advances in genetics.97
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